Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-02-22
2011-11-29
Landau, Sharmila G. (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S044000
Reexamination Certificate
active
08067431
ABSTRACT:
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
REFERENCES:
patent: 4223163 (1980-09-01), Guilloty
patent: 4366159 (1982-12-01), Magruder
patent: 4587046 (1986-05-01), Goodman et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4719215 (1988-01-01), Goldberg
patent: 4730048 (1988-03-01), Portoghese
patent: 4801575 (1989-01-01), Pardridge
patent: 4806556 (1989-02-01), Portoghese
patent: 4861781 (1989-08-01), Goldberg
patent: 5053228 (1991-10-01), Mori et al.
patent: 5099074 (1992-03-01), Mueller et al.
patent: 5102887 (1992-04-01), Goldberg
patent: 5122614 (1992-06-01), Zalipsky
patent: 5130126 (1992-07-01), Koyama et al.
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5225206 (1993-07-01), Fushimi et al.
patent: 5250542 (1993-10-01), Cantrell et al.
patent: 5270328 (1993-12-01), Cantrell et al.
patent: 5298410 (1994-03-01), Phillips et al.
patent: 5320840 (1994-06-01), Camble et al.
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5434171 (1995-07-01), Frank et al.
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5567422 (1996-10-01), Greenwald
patent: 5569450 (1996-10-01), Duan et al.
patent: 5612460 (1997-03-01), Zalipsky
patent: 5618926 (1997-04-01), Salamone et al.
patent: 5637749 (1997-06-01), Greenwald
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5714639 (1998-02-01), Bowman et al.
patent: 5854208 (1998-12-01), Jones et al.
patent: 5866164 (1999-02-01), Kuczynski et al.
patent: 5922675 (1999-07-01), Baker et al.
patent: 5972954 (1999-10-01), Foss et al.
patent: 6011008 (2000-01-01), Domb et al.
patent: 6316644 (2001-11-01), Chung et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 6380405 (2002-04-01), Ekwuribe et al.
patent: 6419959 (2002-07-01), Walter et al.
patent: 6451806 (2002-09-01), Farrar
patent: 6461603 (2002-10-01), Bentley et al.
patent: 6515100 (2003-02-01), Harris
patent: 6518239 (2003-02-01), Kuo et al.
patent: 6541508 (2003-04-01), Ekwuribe et al.
patent: 6565885 (2003-05-01), Tarara et al.
patent: 6703381 (2004-03-01), Ekwuribe et al.
patent: 6713454 (2004-03-01), Ekwuribe et al.
patent: 6815530 (2004-11-01), Ekwuribe et al.
patent: 6835802 (2004-12-01), Ekwuribe et al.
patent: 6858580 (2005-02-01), Ekwuribe et al.
patent: 6903082 (2005-06-01), Ekwuribe et al.
patent: 6930090 (2005-08-01), Ekwuribe et al.
patent: 6943148 (2005-09-01), Ekwuribe et al.
patent: 7056500 (2006-06-01), Bentley et al.
patent: 2002/0169125 (2002-11-01), Leung et al.
patent: 2002/0182172 (2002-12-01), Bentley et al.
patent: 2003/0044402 (2003-03-01), Nelson
patent: 2003/0105275 (2003-06-01), Bentley et al.
patent: 2003/0124086 (2003-07-01), Bentley et al.
patent: 2003/0161791 (2003-08-01), Bentley et al.
patent: 2003/0203961 (2003-10-01), Ekwuribe et al.
patent: 2004/0023852 (2004-02-01), Roberts et al.
patent: 2004/0082620 (2004-04-01), Craig et al.
patent: 2005/0136031 (2005-06-01), Bentley et al.
patent: 2006/0105046 (2006-05-01), Bentley et al.
patent: 2006/0182692 (2006-08-01), Fishburn et al.
patent: 2009/0221766 (2009-09-01), Cheng et al.
patent: 19632440 (1998-02-01), None
patent: 0822218 (1998-02-01), None
patent: 0995757 (2000-04-01), None
patent: 01207320 (1989-08-01), None
patent: WO 93/24476 (1993-12-01), None
patent: WO 96/21469 (1996-07-01), None
patent: WO 97/14740 (1997-04-01), None
patent: WO 99/30727 (1999-06-01), None
patent: WO 99/45964 (1999-09-01), None
patent: WO 01/12230 (2001-02-01), None
patent: WO 01/19407 (2001-03-01), None
patent: WO 01/47562 (2001-07-01), None
patent: WO 01/62299 (2001-08-01), None
patent: WO 02/43772 (2002-06-01), None
patent: WO 02/065988 (2002-08-01), None
patent: WO 02/089789 (2002-11-01), None
patent: WO 02/098949 (2002-12-01), None
patent: WO 03/032990 (2003-04-01), None
patent: WO 03/037384 (2003-05-01), None
patent: WO 03/037385 (2003-05-01), None
patent: WO 03/051113 (2003-06-01), None
patent: WO 03/079972 (2003-10-01), None
patent: WO 03/101476 (2003-12-01), None
patent: WO 2004/043396 (2004-05-01), None
patent: WO 2004/082620 (2004-09-01), None
patent: WO 2005/012335 (2005-02-01), None
patent: WO 2005/016240 (2005-02-01), None
patent: WO 2005/051327 (2005-06-01), None
patent: WO/2005/058367 (2005-06-01), None
ADIS International, “Insulin Inhalation-pfizerlNektar Therapeutics HMR 4006, Inhaled PEG-Insulin-Nektar, PEGylated Insulin-Nektar,” Drugs in R&D, vol. 5, Issue. 3, p. 166-170, 2004.
Antonian, et al., “PEGylation governs the disposition and metabolism ofirinotecan following administration of NKTR-102, a novel PEGylated-irinotecan conjugate,” 14thEuropean Cancer Conference (ECCO 14), 2 pages (Abstract & Poster), Sep. 23-27, 2007, Barcelona, Spain.
Asai et al., “Naloxone Inhibits Gastric Emptying in the Rat”, Anesth. Analg., 1999, pp. 204-208, vol. 88.
Batz et al., “Pharmakologisch aktive Polymere,” Arzneimittel-Forshung 1977 pp. 1884-1888 (English summary provided).
Bennett et al., “Drug-Coupled Poly(Amino Acids) as Polymeric Prodrugs”, Journal of Bioactive and Compatible Polymers, 1988, pp. 44-52, vol. 3.
Bennett et al., “Biodegradable Polymeric Prodrugs of Naltrexone”, Journal of Controlled Release, 1991, pp. 43-52, vol. 16, Nos. 1/2.
Chen et al., “Synthesis and Properties of ABA Amphiphiles”, J. Org. Chem., 1999; pp. 6870-6873, vol. 64.
Cryan, “Carrier-based Strategies for Targeting Protein and Peptide Drugs to the Lungs”, The AAPS Journal (http://www.aapsj.org), 2005; pp. E20-E41, vol. 7 (1).
Davies, et al., “Physiological Parameters in Laboratory Animals and Humans,” Pharrn. Res. vol. 10, Issue 7, p. 1093-1095, 1993.
Donovan, et al., Absorption of Polyethylene Glycols 600 Through 2000: The Molecular Weight Dependence of Gastrointestinal and Nasal Absorption, Pharrn. Res., vol. 7, Issue 8, 1990.
Dorger, et al., “Phenotypic and functional differences between rat alveolar, pleural, and peritoneal macrophages,” Exp. Lung Res., vol. 27, Issue. 1, p. 65-76, 2001.
Eldon, et al., “Antitumor activity and pharmacokinetics ofNKTR-102, a novel PEGylated-irinotecan C6 conjugate, in irinotecan-resistant colorectal tumors implanted in mice,” 14th European Cancer Conference ECCO 14, 2 pages (Abstract & Poster), Sep. 23, 2007.
Eldon, et al., “NKTR-118 (Oral PEG-Naloxol), a PEGylated Derivative of Naloxone: Demonstrations of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models,” Poster 28 presented at the American Academy of Pain Management 18thAnnual Clinical Meeting; Sep. 27-30, 2007; Las Vegas, NV.
Enzon Pharmaceuticals, Macromolecular Engineering Technologies, pp. 1-14, (2004).
Erez et al., “Narcotic Antagonistic Potency of Bivalent Ligands Which Contain B-Naltrexarnine. Evidence for Bridging between Proximal Recognition Sites”,J. Med. Chem., 1982, pp. 847-849, vol. 25, No. 7.
Ertl et al., “Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”, J. Med. Chem., 2000; pp. 3714-3717, vol. 43.
Fishburn, et al., “The Pharmacology of PEGylation: Balancing PO with PK to Generate Novel Therapeutics,” J. Pharm. Sci., p. 1-17, 2008.
Fi
Fishburn C. Simone
Gursahani Hema
Kuo Mei-Chang
Leach Chester
Lechuga-Ballesteros David
Jones Day
Landau Sharmila G.
Love Trevor
Nektar Therapeutics
LandOfFree
Chemically modified small molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemically modified small molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically modified small molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293401